Acute presentation of vasospastic angina induced by oral capecitabine: a case report

Journal of Medical Case Reports

Konstantinos Charalabopoulos¹  Theodosis Bitsis³  Afroditi Tsiakou²  Ilias Dimitrelos³  Christos Graidis⁴  Dimokritos Dimitriadis⁴  Georgios Dimitriadis³  Christos Golias³ 

[1] Department of Physiology, Clinical Unit, Medical Faculty, Democritus University of Thrace, Panepistimioupoli, Dragana 68100 Alexandroupolis, Greece;Department of Cardiology, Preveza State Hospital, Selefkias 2, Preveza 48100 Greece;Department of Cardiology, Serres State Hospital, 2nd km E.O Serrwn-Dramas, Serres 62100 Greece;Department of Interventional Cardiology, Kyanous Stavros Hospital, Vizyis-Vyzantos 1, Thessaloniki 54636 Greece

关键词: Vasospastic angina;    Cardiotoxicity;    Capecitabine;    Acute coronary syndrome;   

Others  :  822903
DOI  :  10.1186/1752-1947-8-18

 received in 2013-05-31, accepted in 2013-11-11,  发布年份 2014

【 摘 要 】

Introduction

Oral capecitabine is an oral prodrug of 5-fluorouracil that has been integrated into the management of multiple cancer types because of the convenience of administration and its efficacy compared with 5-fluorouracil. Capecitabine mimics the pharmacokinetics of intravenous 5-fluorouracil. While cardiac events associated with the use of 5-fluorouracil are a well-known side effect, capecitabine-induced cardiotoxicity has only been rarely reported.

Case presentation

We present a case of a 46-year-old woman of Greek ethnicity who presented to our institution with an operated gastric sarcoma who experienced capecitabine-induced vasospastic angina. Primarily a clinical diagnosis of a possible acute coronary syndrome was proposed and the patient was admitted to the hospital for further investigation which was proved between normal limits. After a witnessed episode of angina, her prior history of capecitabine intake and an undertaken further imaging investigation we associated anginal symptoms and signs with vasospastic angina induced by capecitabine 36 hours prior to hospital admission.

Conclusion

Cardiologists should be aware of the potential cardiac hazards of capecitabine, especially in patients with cardiovascular risk factors. Due to the increasing usage of capecitabine during the last years, patients should be warned for the possibility of chest pain, particularly during the first few days of capecitabine treatment. Specifically, patients developing acute coronary syndrome should not be retreated with capecitabine. On the other hand, due to its promising antitumoral efficacy, its use should not be discouraged.

【 授权许可】

   
2014 Golias et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Tsibiribi P, Descotes J, Lombard-Bohas C, Barel C, Bui-Xuan B, Belkhiria M, Tabib A, Timour Q: Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Bull Cancer 2006, 93:E27-E30.
• [2]Aksoy S, Karaca B, Dinçer M, Yalçin S: Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient. Ann Pharmacother 2005, 39:573-574.
• [3]Rizvi AA, Schauer P, Owlia D, Kallal JE: Capecitabine-induced coronary vasospasm: a case report. Angiology 2004, 55:93-97.
• [4]Schnetzler B, Popova N, Collao Lamb C, Sappino AP: Coronary spasm induced by capecitabine. Ann Oncol 2001, 12:723-724.
• [5]Walko CM, Lindley C: Capecitabine: a review. Clin Ther 2005, 27:23-44.
• [6]Ginghina C, Bejan I, Ceck CD: Modern risk stratification in coronary heart disease. J Med Life 2011, 4:377-386.
• [7]Saif MW, Shah MM, Shah AR: Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009, 8:191-202.
• [8]Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N: Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008, 134:75-82.
• [9]Jensen SA, Sørensen JB: Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006, 58:487-493.
• [10]Duncker DJ, Bache RJ: Regulation of coronary blood flow during exercise. Physiol Rev 2008, 88:1009-1086.
• [11]Shoemaker LK, Arora U, Rocha Lima CM: 5-fluorouracil -induced coronary vasospasm. Cancer Control 2004, 11:46-49.
• [12]Südhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, Schmiegel W: 5-fluorouracil induces arterial vasocontractions. Ann Oncol 2004, 15:661-664.
• [13]Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M: Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002, 13:797-801.
• [14]Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P, Xeloda Colorectal Cancer Study Group: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001, 19:4097-4106.
• [15]Kuppens IE, Boot H, Beijnen JH, Schellens JH, Labadie J: Capecitabine induces severe angina-like chest pain. Ann Intern Med 2004, 140:494-495.